Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up
about
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVVirological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in CanadaCost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cellsMore effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogensLiver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes?Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy.Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient.Towards an ideal antiretroviral regimen for the global HIV epidemic.Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.Factors associated with early virological response in HIV-infected individuals starting antiretroviral therapy in Brazil (2014-2015): results from a large HIV surveillance cohort.Expert consensus statement on the science of HIV in the context of criminal lawBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26783253-9ED6B0CF-F9BB-4A77-80BB-837E59DB1372Q26799712-D61DBEBD-3778-440A-B43E-5A73218A1D62Q33584656-EF6BCF46-9CDE-48F5-9BF4-30F9137D591DQ34478840-B55B6DB9-EE3C-40D2-A0F1-28A1F64F418FQ35158119-790ED2A1-9F7C-4DA1-BCFE-073812BA46B7Q35903617-2C1D01DC-76EC-4A1E-B442-9BF12BCE65A0Q35930384-8C2E973A-3B08-402F-93D2-4F5556E0289DQ36202747-6EDC8BE7-B0DB-403F-9EB7-67B8559FD8CAQ36610081-446E848D-C37D-44DB-81DE-56142C3EF395Q37090265-9867517A-05F6-4C4E-97B9-AC0BD294C521Q38606313-F39E194B-2F41-4C48-930D-9A0734CA864DQ38811335-DA200841-4799-4211-AEEA-3986F7472DBEQ39263069-F546617F-3886-4269-9A47-BF006ED9509DQ39412054-E4C7BBD4-318F-452E-BAA5-26CE1C0118ABQ40072239-365DD100-FFE1-4D1A-A0BF-6D8E5C8C8EF0Q40585903-01F1AD73-8F3F-4F51-8A22-3FD1189C2D68Q40677725-E2665EAB-7488-440A-88C1-051596CAFA43Q40922638-FB680B84-BA0C-4E77-AE5C-E8D4BEA72D0DQ41183328-277983A0-EE4E-4ACE-98D1-3B12515C9133Q42334785-0324DE2F-0EE0-4CB1-925D-5F5B921D3A9DQ47255041-F927E294-C6B9-4FF7-83F5-D95E7CE849D9Q47568887-C5D27C59-165B-4335-B0C2-94C33D7E5672Q52725488-B1F62E16-AB88-4F0E-9470-9349E62F805FQ56911620-D737ED15-24D6-4E36-9147-00EB952A0522Q57180790-99B0B2A2-220D-40D9-A80A-1CA9B68F3F99
P2860
Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@ast
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@en
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@nl
type
label
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@ast
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@en
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@nl
prefLabel
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@ast
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@en
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@nl
P2860
P31
P921
P1433
P1476
Efficacy of initial antiretrov ...... ith up to 144 weeks' follow-up
@en
P2093
Andrew Carr
Frederick J Lee
P2860
P304
P356
10.1371/JOURNAL.PONE.0097482
P407
P50
P5008
P577
2014-05-15T00:00:00Z